^
Association details:
| Biomarker: | CCNE1 amplification |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
974 - Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification
Published date:
03/10/2021
Excerpt:
A multicenter phase 2 study was conducted to assess the antitumor activity of adavosertib in patients with CCNE1 amplified advanced refractory solid tumors.....In 13 patients with measurable high-grade serous ovarian cancer, 5 achieved PR (38.5%) and 8 had stable disease ≥6 months/PR (61.5%). Other PRs were seen in 1 urothelial carcinoma and 1 melanoma.
